Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Charcot-Marie-Tooth disease type 1 (CMT1) is a group of autosomal dominant demyelinating peripheral neuropathies characterized by distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity.
No HPO annotations are available for this condition.
Hereditary neuropathy with liability to pressure palsies (HNPP) is characterized by recurrent acute sensory and motor neuropathy in a single or multiple nerves. The most common initial manifestation is the acute onset of a non-painful focal sensory and motor neuropathy in a single nerve (mononeuropathy) . Some individuals experience transient sensory phenomena without weakness. A history of actual physical minor compression of the nerve may or may not be present. The first attack generally occurs in the second or third decade (age range: 2-70 years; mean 37 years) but could be at any age. With the widespread availability of molecular genetic testing, reports of early onset have become increasingly common .
Hereditary neuropathy with liability to pressure palsies (HNPP) should be suspected in individuals with the following clinical findings, electrophysiologic studies, imaging studies, and family history.
Typical clinical findings
Recurrent acute focal sensory and motor neuropathies mainly at entrapment sites
Painless nerve palsy after minor trauma or compression
No approved treatments are currently available for Charcot-Marie-Tooth disease type 1. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for Charcot-Marie-Tooth disease type 1, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Charcot-Marie-Tooth disease type 1. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Table 3.
Recommended Surveillance for Individuals with HNPP
System/Concern | Evaluation | Frequency
| Screening neurologic exam focused on muscle atrophy, strength, sensory loss | Annually
Eval for neuropathic pain
1 clinical trial registered. Pipeline includes 1 PHASE3.
136 publications have been identified in PubMed for Charcot-Marie-Tooth disease type 1. Research spans Basic Science / Preclinical (35%), Case Report / Case Series (22%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 48 | 35% |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:07 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease type 1
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Evidence on physical examination of previous nerve palsy such as focal weakness, atrophy, or sensory loss
Complete spontaneous recovery from neuropathies (in 50% of occurrences) within weeks
Mild-to-moderate pes cavus foot deformity (in 4%-40% of individuals)
Electrophysiologic studies
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
The signs and symptoms of compression neuropathy in hereditary neuropathy with liability to pressure palsies (HNPP) are the same as those of the acquired type. Thus, HNPP is part of the broad differential diagnosis of both compression neuropathies and general peripheral neuropathies, including the hereditary neuropathies and Charcot-Marie-Tooth (CMT) syndrome (see CMT Overview).
Compression neuropathies. Pressure palsies are most commonly the result of environmentally acquired physical compression of peripheral nerves. The most common are carpal tunnel syndrome with compression of the median nerve at the wrist,* peroneal pressure palsy with compression of the superficial peroneal nerve at the fibular head, and ulnar nerve compression at the elbow.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Biomarker and diagnostic research for Charcot-Marie-Tooth disease type 1 has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
allogeneic mesenchymal stem cells derived neuronal regeneration promoting cells | allogeneic mesenchymal stem cells derived neuronal regeneration promoting cells | Cellatoz Therapeutics, Inc. | 2022 | — | Designated |
To establish the extent of disease and needs in an individual diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 2.
Recommended Evaluations Following Initial Diagnosis in Individuals with HNPP
System/Concern | Evaluation | Comment
| Neurologic eval | To evaluate for pain determine:
Extent of weakness atrophy, pes cavus, gait stability, sensory loss
If there are assoc manifestations (e.g., focal atrophy or sensory loss in less common sites of entrapment)
If affected person /or a family member has had episodes of acute transient nerve palsy
| Orthopedics/ physical medicine rehab/ PT/OT evaluation | To incl assessment of:
Gross motor fine motor skills need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
Feet for evidence of pes cavus need for AFOs, specialized shoes
Mobility, ADL, need for adaptive devices
Need for handicapped parking
Genetic
counseling | By genetics professionals1 | To inform affected persons families re nature, MOI, implications of HNPP to facilitate medical personal decision making
Family support
resources | Assess need for:
Community resources (e.g., Parent to Parent);
Social work involvement for parental support.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Activities that are risk factors for pressure palsies include the following :
Prolonged sitting with legs crossed
Prolonged leaning on elbows
Occupations requiring repetitive movements of the wrist
Rapid weight loss
Wearing a heavy backpack on shoulders
Particular care must be taken in positioning during surgery (particularly knee surgery) to avoid nerve compression . Vincristine, commonly used in the chemotherapy of lymphoma, has been reported to exacerbate HNPP, as other potential neurotoxic chemotherapy or agents . Medications that are toxic or potentially toxic to persons with CMT comprise a spectrum of risk ranging from definite high risk to negligible risk. See the Charcot-Marie-Tooth Association website (pdf) for an up-to-date list.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
1 trial found
OT (fine motor skills) ADL
| For pressure sores or poorly fitting footwear | Annually by physician; at more frequent intervals by affected person
ADL = activities of daily living; OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Estimated prevalence: 1-5 in 10,000 (Uncommon).
30 |
22% |
Disease patterns and progression | 21 | 15% |
Research summaries | 10 | 7% |
New treatment approaches | 10 | 7% |
Testing and diagnosis research | 9 | 7% |
Clinical study results | 8 | 6% |
Sobanska A (2026). [PMID: 41507865](https://pubmed.ncbi.nlm.nih.gov/41507865/). *BMC Neurol*. [Epidemiology / Natural History]
Novello BJ (2026). [PMID: 33085316](https://pubmed.ncbi.nlm.nih.gov/33085316/). *Unknown Journal*. [Diagnostic / Biomarker]
Woo YH (2026). [PMID: 41750400](https://pubmed.ncbi.nlm.nih.gov/41750400/). *Biomolecules*. [Review / Meta-Analysis]
Kalita M (2026). [PMID: 41334667](https://pubmed.ncbi.nlm.nih.gov/41334667/). *Neurol Neurochir Pol*. [Review / Meta-Analysis]
Pagliari E (2026). [PMID: 41486111](https://pubmed.ncbi.nlm.nih.gov/41486111/). *J Biomed Sci*. [Gene Therapy / Novel Therapeutics]
Kramarz C (2026). [PMID: 42231561](https://pubmed.ncbi.nlm.nih.gov/42231561/). *J Peripher Nerv Syst*. [Epidemiology / Natural History]
Nolasco GA (2026). [PMID: 41000004](https://pubmed.ncbi.nlm.nih.gov/41000004/). *Annals of clinical and translational neurology*. [Basic Science / Preclinical]
Glāzere I (2026). [PMID: 41699397](https://pubmed.ncbi.nlm.nih.gov/41699397/). *Sci Rep*. [Diagnostic / Biomarker]
Wang M (2026). [PMID: 41548771](https://pubmed.ncbi.nlm.nih.gov/41548771/). *Pharmacol Res*. [Basic Science / Preclinical]
Koutsis G (2026). [PMID: 41782179](https://pubmed.ncbi.nlm.nih.gov/41782179/). *Journal of the peripheral nervous system : JPNS*. [Basic Science / Preclinical]